Replies to post #203452 on Biotech Values

[DewDiligence]

MSLI -19% on soft FY2017 guidance—and dazzling doublespeak:

http://finance.yahoo.com/news/merus-labs-reports-fiscal-q4-123000164.html

Fiscal 2017 will be a transition year for Merus, and the focus will be on operational effectiveness; optimizing sales, streamlining expenses, assessing debt structure, and enhancing systems and processes.

LOL. That’s a longwinded way of saying FY2017 is going to be a crummy year.